ArticleScience translational medicine2021
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models.
Open access · hybridAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 66 citations in OpenAlex.
- Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.PLoS medicine · 2026Trial
- Unveiling Mucorales infections: A cutting-edge longitudinal imaging approach for real-time infection and host-response monitoring inVirulence · 2026Article
- Camelid VHHs as a Versatile Platform for Combating Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2026Review
- An integrated cell and medium engineering approach for production of a nanobody fusion in Saccharomyces cerevisiae.Applied microbiology and biotechnology · 2026Article
- Article
- Review
- Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation.Drug delivery and translational research · 2025Article
- Long-Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection.Advanced nanobiomed research · 2025Article
- Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base.Nature communications · 2025Article
- Identification and characterization of a broadly neutralizing and protective nanobody against the HA1 domain of H5 avian influenza virus hemagglutinin.Journal of virology · 2025Article
- Nanobodies: From Discovery to AI-Driven Design.Biology · 2025Review
- Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry.Viruses · 2025Article
- Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections.Frontiers in immunology · 2025Review
- Unlocking the potential ofFrontiers in bioinformatics · 2025Review
- Backstage Heroes-Yeast in COVID-19 Research.International journal of molecular sciences · 2024Review
- Structure defining of ultrapotent neutralizing nanobodies against MERS-CoV with novel epitopes on receptor binding domain.PLoS pathogens · 2024Article
- Structural basis for potent neutralization of human respirovirus type 3 by protective single-domain camelid antibodies.Nature communications · 2024Article
- Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.Journal of nanobiotechnology · 2024Review
- Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted.EBioMedicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors at 9 institutions in 4 countries.
Bert SchepensVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-2028-1984
Loes van SchieVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0003-2588-9750
Wim NerinckxVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-6563-8342
Kenny RooseVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-5270-4603
Wander Van BreedamVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.
Daria FijalkowskaVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-2084-146X
Simon DevosVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.
Wannes WeytsVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-8275-7853
Sieglinde De CaeVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.
Sandrine VanmarckeVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-0955-7556
Chiara LonigroVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-9523-7929
Hannah EeckhautVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0003-1519-3653
Dries Van HerpeVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0003-2842-4385
Jimmy BorlooVIB Discovery Sciences, Technologiepark-Zwijnaarde 104B, 9052 Ghent, Belgium.
Ana Filipa OliveiraVIB Discovery Sciences, Technologiepark-Zwijnaarde 104B, 9052 Ghent, Belgium.ORCID 0000-0001-9334-5101
João Paulo Portela CataniVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-4866-3933
Sarah CreytensVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0001-7262-3117
Dorien De VliegerVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.
Gitte MichielsenVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0003-1378-8661
Jackeline Cecilia Zavala MarchanVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-8996-8741
George D MoschonasVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0001-6739-9341
Iebe RosseyVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-0795-972X
Koen SedeynVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-1303-1629
Annelies Van HeckeVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.
Xin ZhangKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-8520-1060
Lana LangendriesKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-6450-6324
Sofie JacobsKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-8657-6841
Sebastiaan Ter HorstKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-7981-6376
Laura SeldeslachtsKU Leuven Department of Imaging and Pathology, Biomedical MRI and MoSAIC, 3000 Leuven, Belgium.ORCID 0000-0002-9562-2923
Laurens LiesenborghsKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-5616-8548
Robbert BoudewijnsKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-5984-7279
Hendrik Jan ThibautKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-5785-8276
Kai DallmeierKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-8117-9166
Greetje Vande VeldeKU Leuven Department of Imaging and Pathology, Biomedical MRI and MoSAIC, 3000 Leuven, Belgium.ORCID 0000-0002-5633-3993
Birgit WeynandKU Leuven Department of Imaging and Pathology, Division of Translational Cell and Tissue Research, Translational Cell and Tissue Research, 3000 Leuven, Belgium.ORCID 0000-0003-4246-6303
Julius BeerInstitute of Virology, Medical Center University Freiburg, 79104 Freiburg, Germany.ORCID 0000-0002-0628-6543
Daniel SchnepfInstitute of Virology, Medical Center University Freiburg, 79104 Freiburg, Germany.ORCID 0000-0002-7528-981X
Annette OhnemusInstitute of Virology, Medical Center University Freiburg, 79104 Freiburg, Germany.ORCID 0000-0002-4356-3175
Isabel RemoryDepartment of Medical Imaging, In vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.ORCID 0000-0003-4785-0371
Caroline S FooKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-6380-4917
Rana AbdelnabiKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-9771-7312
Piet MaesKU Leuven, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-4571-5232
Suzanne J F KapteinKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-7935-0219
Joana Rocha-PereiraKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-8299-3787
Dirk JochmansKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-9265-6028
Leen DelangKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-8874-675X
Frank PeelmanVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0001-6852-8731
Peter StaeheliInstitute of Virology, Medical Center University Freiburg, 79104 Freiburg, Germany.ORCID 0000-0001-7057-6177
Martin SchwemmleInstitute of Virology, Medical Center University Freiburg, 79104 Freiburg, Germany.ORCID 0000-0002-2972-6855
Nick DevoogdtDepartment of Medical Imaging, In vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.ORCID 0000-0001-9220-4833
Dominique TersagoExeVir, Rijvisschestraat 120, 9052 Ghent, Belgium.
Massimiliano GermaniUCB Celltech, Slough, SL1 3WE, UK.ORCID 0000-0001-8286-9954
James HeadsUCB Celltech, Slough, SL1 3WE, UK.ORCID 0000-0003-2444-9091
Alistair HenryUCB Celltech, Slough, SL1 3WE, UK.ORCID 0000-0002-9081-1055
Andrew PopplewellUCB Celltech, Slough, SL1 3WE, UK.
Mark EllisUCB Celltech, Slough, SL1 3WE, UK.ORCID 0000-0001-6076-5994
Kevin BradyUCB Celltech, Slough, SL1 3WE, UK.
Alison TurnerUCB Celltech, Slough, SL1 3WE, UK.
Bruno DombrechtVIB Discovery Sciences, Technologiepark-Zwijnaarde 104B, 9052 Ghent, Belgium.ORCID 0000-0003-3824-3975
Catelijne StortelersVIB Discovery Sciences, Technologiepark-Zwijnaarde 104B, 9052 Ghent, Belgium.
Johan NeytsKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-0033-7514
Nico CallewaertVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0003-2069-6917
Xavier SaelensVIB-UGent Center for Medical Biotechnology, VIB, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium.ORCID 0000-0002-3861-6965
Ghent University · BERega Institute for Medical Research · BEUCB Pharma (United Kingdom) · GBVIB-UGent Center for Plant Systems Biology · BEUniversity Medical Center Freiburg · DEKU Leuven · BEUniversity of Freiburg · DEVrije Universiteit Brussel · BECell and Tissue Systems (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Broadly neutralizing antibodies are an important treatment for individuals with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody-based therapeutics are also essential for pandemic preparedness against future
Indexed as
COVID-19Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingAntibodies, ViralHumansModels, AnimalSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.